Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Ensuring psychedelic treatments and research do not leave anyone behind

Neuropsychopharmacology volume 49, pages 294–295 (2024)Cite this article

Subjects

Psychedelics are a promising approach to caring for persons living with severe mental illness. However, as with all clinical treatments and research in the US, health equity concerns must be considered and addressed. Ensuring health equity and health justice in psychedelic care delivery and research will require strategies to not only reduce disparities and preempt future disparities among minoritized and marginalized populations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Thrul J, Garcia-Romeu A. Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs Educ Prev Policy. 2021;28:211–4.

  2. Williams MT, Davis AK, Xin Y, Sepeda ND, Grigas PC, Sinnott S, et al. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs Educ Prev Policy. 2021;28:215–26.

  3. Jones GM, Nock MK. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and sociality. Nat Sci Rep. 2022;12:16976.

    CAS  Google Scholar 

  4. Garcia-Romeu A, Barrett FS, Carbonaro TC, Johnson MW, Griffith RR. Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches. J Psychopharmacol. 2021;35:353–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18:245.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shalit N, Rehm J, Lev-Ran S. Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III. Addict Behav. 2019;89:35–43.

    Article  PubMed  Google Scholar 

  7. To learn more about the Health for All Project, go to https://healthforallproject.org/about/. Accessed May 2023.

  8. Smith DT, Faber SC, Buchanan NT, Foster D, Green L. The need for psychedelic-assisted therapy in the black community and the burdens of its provision. Front Psychiatry. 2021;12:774736.

    Article  PubMed  Google Scholar 

  9. Rea K, Wallace B. Enhancing equity-oriented care in psychedelic medicine: utilization of the EQUIP framework. Int J Drug Policy. 2021;98:103429.

    Article  PubMed  Google Scholar 

  10. Pilecki B, Luoma JB, Bathje GJ, Rhea J, Narloch VF. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J. 2021;18:40.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Glasgow RE, Vinson C, Chambers D, Khoury MJ. National institutes of health approaches to dissemination and implementation science: current and future directions. AJPH. 2012;102:1274–81.

    Article  Google Scholar 

  12. Bauer MS, Damschroder L, Hegedorn H, Smith J, Kilbourne AM. An introduction to implementation science for the non-specialist. BMC Psychol. 2015;3:32.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50:217–26.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Snyder JE, Upton RD, Hassett TC, Lee H, Nouri Z, Dill M. Black representation in the primary care physician workforce and its association with population life expectancy and mortality rates int the US. JAMA Netw Open. 2023;6:e236687.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Peek ME. Increasing representation of Black primary care physicians—a critical strategy to advance racial health equity. JAMA Netw Open. 2023;6:e236678.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Alsan M, Garrick O, Graziani GC, National Bureau of Economic Research. Does diversity matter for health? Experimental evidence from Oakland. NBER Working Paper. JEL No. C93,I12, I14. 2018.

  17. Fotiou E. The role of Indigenous knowledges in psychedelic science. J Psychedelic Stud. 2020;4:16–23.

    Article  Google Scholar 

  18. George JR, Michaels TI, Sevelius J, Williams MT. The psychedelic renaissance and the limitations of a White-dominant medical framework: a call for indigenous and ethnic minority inclusion. J Psychedelic Stud. 2020;4:4–15.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Obstetrics and Gynecology, Preventive Medicine and Medical Social Sciences and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

    Melissa A. Simon

Authors
  1. Melissa A. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melissa A. Simon.

Ethics declarations

Competing interests

MAS serves as a member of the NIH Advisory Committee for the Office on Women’s Health (ACRWH ORWH) Research at NIH and as a member of the CDC Community Preventive Services Task Force (CPSTF) and her written views are her own and not necessarily those expressed by the NIH ORWH nor CDC CPSTF.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simon, M.A. Ensuring psychedelic treatments and research do not leave anyone behind. Neuropsychopharmacol. 49, 294–295 (2024). https://doi.org/10.1038/s41386-023-01710-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-023-01710-4

Search

Advanced search

Quick links